CTCs in:none of the healthy controls and other cancer patients4% of the patients with elevated PSA levels and negative prostate biopsies or TURP24% of the patients before RP51% of the patients with progressive PCa9% of the patients with no evidence of disease <5 years after treatmentNone of the patients with no evidence of disease >5 years after treatment. This evidence concerns the gene KLK3 and cancer.